Literature DB >> 6740074

Mucosal immune response to poliovirus vaccines in childhood.

P L Ogra.   

Abstract

Comparative evaluation of the systemic and secretory antibody response to live attenuated (oral) poliovirus vaccine ( OPV ) or inactivated poliovirus vaccine (IPV) has suggested that both vaccines are highly effective in inducing seroconversion and in preventing paralytic poliomyelitis. However, parenteral immunization with IPV does not appear to be highly effective in inducing secretory antibody response in the nasopharynx or alimentary tract during primary immunization. Reimmunization with IPV in subjects previously primed with parenterally administered IPV appears to result in a mild booster effect on the development of secretory antibody response. More significantly, rechallenge by the oral route with OPV in IPV-primed subjects resulted in a marked enhancement of secretory antibody response. In general, no suppression of systemic or secretory response to poliovirus was observed with either form ( OPV vs. IPV) or with route of immunization. These observations are discussed in relation to the immune response observed with other mucosally or parenterally administered antigens. Their implications in the development of oral tolerance are briefly reviewed.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6740074     DOI: 10.1093/clinids/6.supplement_2.s361

Source DB:  PubMed          Journal:  Rev Infect Dis        ISSN: 0162-0886


  17 in total

1.  Secretory immune responses to Mycoplasma pulmonis.

Authors:  M J Steffen; J L Ebersole
Journal:  Infect Immun       Date:  1992-02       Impact factor: 3.441

2.  Orally administered microencapsulated reovirus can bypass suckled, neutralizing maternal antibody that inhibits active immunization of neonates.

Authors:  S B Periwal; T J Speaker; J J Cebra
Journal:  J Virol       Date:  1997-04       Impact factor: 5.103

3.  Modeling population immunity to support efforts to end the transmission of live polioviruses.

Authors:  Kimberly M Thompson; Mark A Pallansch; Radboud J Duintjer Tebbens; Steve G Wassilak; Stephen L Cochi
Journal:  Risk Anal       Date:  2012-09-17       Impact factor: 4.000

4.  Influenza specific antibodies in the female genital tract of mice after oral administration of live influenza vaccine.

Authors:  V Briese; W D Pohl; K Noack; H Tischner; R H Waldman
Journal:  Arch Gynecol       Date:  1987

5.  Foot-and-mouth disease virus 2A protease mediates cleavage in attenuated Sabin 3 poliovirus vectors engineered for delivery of foreign antigens.

Authors:  N M Mattion; E C Harnish; J C Crowley; P A Reilly
Journal:  J Virol       Date:  1996-11       Impact factor: 5.103

6.  Protective anti-reovirus monoclonal antibodies and their effects on viral pathogenesis.

Authors:  K L Tyler; M A Mann; B N Fields; H W Virgin
Journal:  J Virol       Date:  1993-06       Impact factor: 5.103

7.  Release of virus-like particles from cells infected with poliovirus replicons which express human immunodeficiency virus type 1 Gag.

Authors:  D C Porter; L R Melsen; R W Compans; C D Morrow
Journal:  J Virol       Date:  1996-04       Impact factor: 5.103

8.  Protective secretory immunoglobulin A antibodies in humans following oral immunization with Streptococcus mutans.

Authors:  R L Gregory; S J Filler
Journal:  Infect Immun       Date:  1987-10       Impact factor: 3.441

9.  Role of immune cells in protection against and control of reovirus infection in neonatal mice.

Authors:  H W Virgin; K L Tyler
Journal:  J Virol       Date:  1991-10       Impact factor: 5.103

10.  Human Toxoplasma gondii-specific secretory immunoglobulin A reduces T. gondii infection of enterocytes in vitro.

Authors:  D G Mack; R McLeod
Journal:  J Clin Invest       Date:  1992-12       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.